StockNews.com assumed coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research note released on Sunday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Up 1.5 %
Shares of TTNP opened at $3.33 on Friday. The stock has a 50 day moving average price of $3.56 and a 200 day moving average price of $4.21. Titan Pharmaceuticals has a 52-week low of $3.03 and a 52-week high of $14.80.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last announced its quarterly earnings results on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Further Reading
- Five stocks we like better than Titan Pharmaceuticals
- Growth Stocks: What They Are, Examples and How to Invest
- NVIDIA Stock Remains Stunningly Undervalued—Here’s Why
- Stock Market Upgrades: What Are They?
- Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy
- Upcoming IPO Stock Lockup Period, Explained
- U.S. Stocks Sink, Foreign Markets Soar: 3 ETFs to Ride the Wave
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
